Real-world data indicate that ocrelizumab is safe and effective in Latino people with multiple sclerosis (MS), according to a recent report. In a prospective observational study, a total of 305 people with relapsing–remitting MS, primary progressive MS or secondary progressive MS received ocrelizumab during a median follow-up period of 29.5 months. Only one person experienced a relapse, and disability worsened in only 12.4% of participants overall, with the highest risk in the group with secondary progressive MS. The findings provide evidence for efficacy and safety in a group that has been underrepresented in clinical trials of the drug.